Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro

A number of inhibitors of the essential Mycobacterium tuberculosis mycolic acid transporter, MmpL3, are currently under development as potential novel antituberculosis agents. Using the checkerboard method to study the interaction profiles of various antituberculosis drugs or experimental compounds...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wei, Sanchez-Hidalgo, Andrea, Jones, Victoria, de Moura, Vinicius Calado Nogueira, North, E. Jeffrey, Jackson, Mary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2017
Materias:
Susceptibility
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365669/
https://www.ncbi.nlm.nih.gov/pubmed/28115355
http://dx.doi.org/10.1128/AAC.02399-16
Descripción
Sumario:A number of inhibitors of the essential Mycobacterium tuberculosis mycolic acid transporter, MmpL3, are currently under development as potential novel antituberculosis agents. Using the checkerboard method to study the interaction profiles of various antituberculosis drugs or experimental compounds with two different chemotypes inhibiting this transporter (indolcarboxamides and adamantyl ureas), we showed that MmpL3 inhibitors act synergistically with rifampin, bedaquiline, clofazimine, and β-lactams.

Ejemplares similares